Negotiating with a university: tactics and benchmarks
Core idea#
Negotiating with your own university is unusual: the other side is your employer, your PI's employer, the owner of your lab and possibly a future investor, and you'll keep working with them for years. Winning every term at the cost of the relationship is a bad outcome. So is accepting terms that make the company uninvestable because you didn't want to push.
The approach that works:
- Align on the shared goal. The university wants its research to have impact and to share in success; you want a fundable company. Terms that make the company fail serve neither.
- Negotiate the package, not each clause. Equity, royalties, fees, milestones and rights trade against each other (2.08).
- Use benchmarks and investors. Published norms and investor feedback turn "I want more" into "this is what the market requires".
- Move fast where it's standard, and spend time only on the terms that matter for your business.
Who it's for: founders spinning out of a university, institute or research hospital, negotiating a licence, option or equity agreement.
Benchmarks at a glance#
| United States | United Kingdom | India | |
|---|---|---|---|
| University equity |
Usually single digits; leading universities such as MIT and |
USIT landing zone 10– 25% for life sciences ( Cambridge |
Set by institute policy; often small fixed equity, sometimes with |
| Stanford typically around 5% ( Orrick); |
Enterprise); 5–10% for software ( Imperial); |
a choice of royalty instead (2.11) |
|
| average about 4% where equity is granted ( Gunderson Dettmer) |
average fell to 16% in 2024–25( CASRAI on RAEng) |
| United States | United Kingdom | India | |
|---|---|---|---|
| Royalty | Median about 1.75% without and 2.38% with anti-stacking ( Gunderson Dettmer) |
0–5% depending on maturity; 0–2% for software |
Varies; often low single digits or revenue share |
| Upfront fee | Median $17,500 where present ( Gunderson Dettmer); often waived or deferred for startups |
Usually small for spinouts |
Often modest |
| Time to | Weeks to months with | Most spinouts take 4– | Often several months; |
| close | express licences | 12 months ( Mathys & Squire) |
faster at experienced institutes |
The trend: faster, more standard, more founder-friendly#
- In the UK, the 2023 Independent Review of University Spin-out Companies recommended using the USIT Guide as the starting point for terms, publishing deal terms and setting clear expectations on time to complete each stage; the government accepted all its recommendations (Government response; CIC). The review found negotiations on university equity started at an average of 34% (Mathys & Squire); stakes have since fallen sharply.
- Some UK universities have gone further; King's College London moved to 85–100% founder equity in July 2026 (playbook 2.11).
- In the US, many universities publish express licences with fixed terms (for example, Cornell's FastTrack and Tulane's Go Green; playbook 2.08).
- In India, newer institute policies set clearer equity and licensing options (playbook 2.11).
The practical lesson: ask for the standard or express terms first. If your university has them, negotiation may be unnecessary.
Preparing#
- Understand the university's position
- What does its policy say? Equity, royalty, revenue share, standard terms (2.01, 2.11). Who decides? A licensing manager, a committee, a director? What can each approve alone?
- What does it need? Usually: a fair return, protection against reputational risk, diligence so the IP isn't shelved, and compliance with funders' rules (for example, Bayh-Dole in the US).
- What are its constraints? Public bodies and government-linked institutes may have rules on equity, pricing and approvals that staff can't override.
2. Know your leverage#
- You're the best licensee. You know the technology best and are committed to it. Most university inventions are never licensed at all.
- Investors. A lead investor saying "we can't invest on these terms" is the strongest argument you'll have.
- Benchmarks from the university's own past deals, peer universities and published guides.
- Time. Patents age while you negotiate; a deal sooner is worth more to everyone.
3. Know your alternatives#
What happens if you don't agree? Could you develop around the patent, license something else, build on unpatented know-how, or start a different company? A realistic alternative stops you accepting a bad deal; an unrealistic bluff damages trust.
4. Rank your priorities#
Typical founder priorities, in order:
- Scope: exclusive, in the fields and countries you need, including improvements (2.07).
- Investability: total equity and royalty burden investors accept; no vetoes; free assignment (2.09).
- Cash timing: little or nothing payable before revenue or financing (2.08).
- Diligence terms you can meet (2.07).
- Everything else.
Decide in advance which terms you'll trade and which you won't.
5. Build the team#
- A startup lawyer experienced in university licences, ideally paid on deferral or fixed fee.
- An investor or experienced founder to sanity-check terms.
- Your PI or inventor colleagues, who also have a stake (inventor revenue share) and a relationship to protect.
6. Set a timeline#
Agree milestones with the TTO: term sheet, draft licence, final, signature. In the UK, the Independent Review recommended universities state expected timescales (CIC); ask for them.
Tactics in the negotiation#
- Start with a term sheet, not a 40-page licence. Agree the economics and key rights first.
- Anchor with benchmarks, not demands: "The USIT Guide suggests", "your published express licence says", "Gunderson's data shows a median of".
- Bring the investor's view in writing. A short email from your lead investor on what's fundable carries more weight than your opinion.
- Trade, don't concede. Every give should get something back: higher equity for lower royalty, higher milestones for no upfront fee, a sublicence share for free assignment.
- Explain the why. "An annual minimum before revenue drains our runway and makes us less likely to succeed, which hurts your equity."
- Keep the inventors aligned with the company. If the inventors push for higher royalties (because they share in them), the company's interests can diverge from theirs; discuss it openly.
- Escalate politely and rarely. If a term is genuinely blocking, ask for a meeting with the TTO director, together with your investor.
- Write down agreements after each call. It speeds drafting and avoids re-opening points.
Worked example (illustrative)#
A UK materials spinout receives a first offer: 30% university equity with anti-dilution to £5 million raised; a 4% royalty on all products "using" the technology; a £25,000 upfront fee; annual minimums from year two; consent for sublicensing and assignment.
The founders prepare: the USIT landing zone (10–25% equity, 0–5% royalty), the university's two most recent comparable deals (published under its transparency commitment), and an email from their lead investor saying they can't invest above 15% university equity with anti-dilution, or with consent rights on assignment.
| Term | First offer | Agreed |
|---|---|---|
| Equity | 30%, anti-dilution to £5m | 15%, no anti-dilution |
| Term | First offer | Agreed |
|---|---|---|
| Royalty | 4% on anything "using" the technology |
2% on products covered by a valid claim, with anti-stacking to 1% |
| Upfront fee | £25,000 | Waived; £25,000 milestone at Series A |
| Annual minimums |
From year two | From year five, creditable against royalties |
| Sublicensing | Consent required | Permitted; 15% of non-royalty income, excluding funded R&D |
| Assignment | Consent required | Free on sale of substantially all the business |
Time to close: four months, after the university's committee approved the deviation from its standard equity with the investor's letter attached.
Scripts#
Opening the negotiation
"We want a deal that works for the university and that investors will fund. Could we start with your standard or express terms, and a short term sheet, so we can focus our time on the few points that matter for our business?"
Using a benchmark#
"Your proposal is 30% equity with anti-dilution. The USIT Guide landing zone is 10– 25%, and the national average last year was 16%. Our lead investor has said they can't invest above 15% with anti-dilution. Could we work from that?"
Trading terms#
"We understand you need a return. We'd rather pay it when we can: could we replace the upfront fee and early minimums with a payment at Series A and a higher first-sale milestone?"
When you're stuck#
"This point is the one our investors have flagged as blocking. Could we set up a short call with [director] and our lead investor to find a solution?"
Common mistakes#
- Negotiating clause by clause instead of the whole package.
- Not asking for standard or express terms first.
- Arguing from need, not benchmarks.
- Leaving investors out until the end. Their input changes outcomes.
- Bluffing about alternatives.
- Letting it drag. Patent life and momentum are lost; set dates.
- Damaging the relationship. You'll need the university for labs, staff, sponsored research and future IP.
- Signing without a lawyer experienced in university licences.
Related playbooks#
- 2.03 Working with the tech transfer office
- 2.07 Licence anatomy
- 2.08 Royalties, milestones and anti-stacking
- 2.09 Sublicensing and change of control
- 2.11 Spinout equity norms
- 2.14 Using university labs after spinout
Sources#
- Gunderson Dettmer, University license presentation (2024).
- Orrick, How much should a university hold in IP-based spinouts?.
- UK: Independent Review government response; CIC summary; Mathys & Squire summary; Cambridge Enterprise, USIT landing zone; Imperial, USIT for Software; CASRAI, RAEng 2026.
Worked example is illustrative. Not legal advice. Last checked November 2026.